ATE335488T1 - Kombinationstherapie mit zd6474 und einem taxan - Google Patents

Kombinationstherapie mit zd6474 und einem taxan

Info

Publication number
ATE335488T1
ATE335488T1 AT02772624T AT02772624T ATE335488T1 AT E335488 T1 ATE335488 T1 AT E335488T1 AT 02772624 T AT02772624 T AT 02772624T AT 02772624 T AT02772624 T AT 02772624T AT E335488 T1 ATE335488 T1 AT E335488T1
Authority
AT
Austria
Prior art keywords
taxan
combination therapy
therapy
combination
Prior art date
Application number
AT02772624T
Other languages
German (de)
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE335488T1 publication Critical patent/ATE335488T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02772624T 2001-11-08 2002-11-06 Kombinationstherapie mit zd6474 und einem taxan ATE335488T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy

Publications (1)

Publication Number Publication Date
ATE335488T1 true ATE335488T1 (de) 2006-09-15

Family

ID=9925430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02772624T ATE335488T1 (de) 2001-11-08 2002-11-06 Kombinationstherapie mit zd6474 und einem taxan

Country Status (22)

Country Link
US (2) US20050043395A1 (https=)
EP (1) EP1446124B1 (https=)
JP (1) JP4694127B2 (https=)
KR (1) KR100959607B1 (https=)
CN (1) CN1298328C (https=)
AR (1) AR037346A1 (https=)
AT (1) ATE335488T1 (https=)
AU (1) AU2002337382B2 (https=)
BR (1) BR0213906A (https=)
CA (1) CA2464758C (https=)
CY (1) CY1106259T1 (https=)
DE (1) DE60213845T2 (https=)
DK (1) DK1446124T3 (https=)
ES (1) ES2269769T3 (https=)
GB (1) GB0126879D0 (https=)
IL (2) IL161744A0 (https=)
MX (1) MXPA04004355A (https=)
NO (1) NO328048B1 (https=)
NZ (1) NZ532525A (https=)
PT (1) PT1446124E (https=)
WO (1) WO2003039551A1 (https=)
ZA (1) ZA200403455B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
SI1474420T1 (sl) * 2002-02-01 2012-06-29 Astrazeneca Ab Spojine kinazolina
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
AU2003278383B2 (en) 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
JP7737455B2 (ja) * 2020-12-22 2025-09-10 ハンミ ファーマシューティカル カンパニー リミテッド Ｓｏｓ１阻害剤としての新規キナゾリン誘導体化合物及びその用途｛ｎｏｖｅｌ ｑｕｉｎａｚｏｌｉｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｓ ｓｏｓ１ ｉｎｈｉｂｉｔｏｒｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
PT910382E (pt) * 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
MXPA01008699A (es) * 1999-02-24 2002-06-21 Uab Research Foundation Derivados de taxano para terapia de cancer dirigida. .
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
IL161744A0 (en) 2005-11-20
EP1446124B1 (en) 2006-08-09
NO20042365L (no) 2004-06-07
CN1298328C (zh) 2007-02-07
DE60213845D1 (de) 2006-09-21
WO2003039551A1 (en) 2003-05-15
JP2005511597A (ja) 2005-04-28
US20050043395A1 (en) 2005-02-24
MXPA04004355A (es) 2004-08-11
DE60213845T2 (de) 2007-03-29
CA2464758C (en) 2010-09-28
JP4694127B2 (ja) 2011-06-08
GB0126879D0 (en) 2002-01-02
CA2464758A1 (en) 2003-05-15
ZA200403455B (en) 2005-08-29
ES2269769T3 (es) 2007-04-01
NO328048B1 (no) 2009-11-16
PT1446124E (pt) 2006-12-29
HK1068546A1 (en) 2005-04-29
IL161744A (en) 2012-01-31
CN1612738A (zh) 2005-05-04
NZ532525A (en) 2006-11-30
KR100959607B1 (ko) 2010-05-27
CY1106259T1 (el) 2011-06-08
AU2002337382B2 (en) 2008-06-12
DK1446124T3 (da) 2006-11-13
KR20050043779A (ko) 2005-05-11
EP1446124A1 (en) 2004-08-18
AR037346A1 (es) 2004-11-03
US20120252827A1 (en) 2012-10-04
BR0213906A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
DE60213845D1 (de) Kombinationstherapie mit zd6474 und einem taxan
DE60326611D1 (de) N und dergleichen
DE60212600D1 (de) Audiocodierung und decodierung
DE60222285D1 (de) Niedrigviscose kratzresistente beschichtungen mit strukturgebenden und inorganischen füllstoffen
DE60308457D1 (de) Adaptive Modulation und Kodierung
GB0116644D0 (en) Electroluminescent materials and devices
DE60228061D1 (de) Maschenware mit öffnung und herstellungsverfahren
EP1494530A4 (en) COMBINATION THERAPY USING TREFLE LEAF PEPTIDES
PL369510A1 (en) Spirocyclic 3-phenyl-3-substituted 4-ketolactams and 4-ketolactones
AU2003290341A8 (en) Electroluminescent materials and devices
IL159215A0 (en) A solution of interleukin-13 and methods utilizing the same
GB0228335D0 (en) Electroluminescent materials and devices
IL159872A0 (en) Gmg-2 polypeptides and their use
DE60304229D1 (de) Pinselabflacher und mit Pinselabflacher ausgerüstete Zeichenvorrichtung
DE60223540D1 (de) Mundschutz und mundschutzfolie
AU2003298129A8 (en) Floor-furnace chimney and the use thereof
DE60238293D1 (de) Anschlussteil und Steckverbinder mit einem solchen Anschlussteil
DE60203475D1 (de) Drosselklappe und Drossel
AU2003302323A8 (en) A method and therapeutic platelets
DE60303601D1 (de) Abgabekopf und betätigungskopf mit einem solchen abgabekopf
SG107563A1 (en) Gate electrodes and the formation thereof
GB2382598B (en) Construction and elongate members therefor
PL363290A1 (en) 1k-polyurethane lacquer and use thereof
GB0228525D0 (en) Polymers and their use
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1446124

Country of ref document: EP